The Manufacturers Life Insurance Company Acquires 18,427 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Posted by Brenda Bartman on Aug 6th, 2026

The Manufacturers Life Insurance Company increased its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report) by 19.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 114,814 shares of the company’s stock after purchasing an additional 18,427 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Structure Therapeutics were worth $5,534,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in GPCR. Sterling Capital Management LLC purchased a new stake in Structure Therapeutics during the first quarter valued at about $28,000. State of Wyoming purchased a new position in shares of Structure Therapeutics in the second quarter worth about $28,000. CWM LLC lifted its stake in shares of Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock valued at $33,000 after acquiring an additional 125 shares during the last quarter. Assetmark Inc. boosted its holdings in Structure Therapeutics by 21.4% during the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after acquiring an additional 449 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in Structure Therapeutics during the 4th quarter worth approximately $127,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Trading Up 1.6%

Shares of Structure Therapeutics stock opened at $50.42 on Thursday. Structure Therapeutics Inc. Sponsored ADR has a 12-month low of $15.80 and a 12-month high of $94.90. The company has a market cap of $3.58 billion, a P/E ratio of -57.95 and a beta of -1.43. The company’s fifty day simple moving average is $47.11 and its two-hundred day simple moving average is $54.45.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. Analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GPCR has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Canaccord Genuity Group began coverage on shares of Structure Therapeutics in a report on Monday, April 27th. They set a “buy” rating and a $101.00 price target for the company. Wall Street Zen upgraded shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Finally, HC Wainwright dropped their target price on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a report on Thursday, June 11th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $110.55.

Get Our Latest Stock Analysis on Structure Therapeutics

Structure Therapeutics Profile

(Free Report)

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.